Nucala (mepolizumab)

pCPA File Number: 22092
Negotiation Status:
Concluded with an LOI
Indication(s):
Severe chronic rhinosinusitis with nasal polyps
Sponsor/Manufacturer:
GlaxoSmithKline Inc.
CDA-AMC Project Number:
SR0735-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: